Industry
Biotechnology
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Loading...
Open
1.47
Mkt cap
45M
Volume
218K
High
1.48
P/E Ratio
-1.04
52-wk high
10.24
Low
1.41
Div yield
N/A
52-wk low
1.33
Portfolio Pulse from Avi Kapoor
August 05, 2024 | 5:07 pm
Portfolio Pulse from Vandana Singh
August 05, 2024 | 3:21 pm
Portfolio Pulse from Avi Kapoor
August 05, 2024 | 2:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 11:12 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 11:12 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 11:41 am
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 2:45 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:11 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.